Dr. Ross Camidge discusses a clinical trial studying patients with advanced stage lung cancer to identify those who may respond to a drug called ponatinib. Both small cell and non small cell lung cancer patients may be eligible. http://bit.ly/UCponatinib

The following piece is from the University of Colorado, where Dr. Camidge and some others there are leading a very novel trial for a small molecularly defined subgroup with specific biomarkers related to fibroblast growth factor receptor-1 (FGFR1) are potential candidates for a trial just launching now with the agent ponatinib, a tyrosine kinase inhibitor (TKI) that hits many targets.